NanoViricides Inc. (NNVC) stock rises during current market trading. Let’s find out why?

CEI Stock
CEI Stock

NanoViricides Inc. (NASDAQ: NNVC) stock gains by 15.23% in the current market trading session. NanoViricides is a firm in the early stages of development that develops antiviral nanoparticles. The Company’s innovative nanoviricide medication candidates are intended to attack and deconstruct encapsulated virus particles.

>> 7 Top Picks for the Post-Pandemic Economy << 

NNVC stock’ Current Update

NanoViricides has finished the process of licensing the human Coronavirus field from TheraCour Pharma for medication research and commercialization. On September 8, 2021, NNVC and TheraCour Pharma signed a licensing deal for the field of antiviral medicines for coronavirus-derived human illnesses.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Read More

Antiviral medications to treat SARS-CoV-2 and its variants, which cause the COVID-19 disease and have resulted in a global pandemic that continues to rampage around the world, wave after wave, as new variants emerge and take root. The license did not need any upfront financial payment, and the remuneration terms were similar to those of previous licenses.

The company thinks that these broad-spectrum anti-coronavirus drugs will remain viable even as the virus persists to mutate and evolve into a variety of dangerous variants. The firm also believes that its own anti-viral nanomachine technology will solve these problems. NanoViricides is actively working on human clinical trials for its two COVID-19 lead drug candidates, NV-CoV-2- and NV-CoV-2-R. The Management says that the necessary preclinical work for putting these drugs into human trials is nearly complete.


NanoViricides has received a global, exclusive, sub-licensable license to use, advertise, offer for sale, import, export, sell, and distribute antiviral medications that cure human Coronavirus infection within the terms of the deal. It makes use of TheraCour’s proprietary and patented technology and intellectual property, including the recently filed patent application. TheraCour will conduct the development of ligands and polymer materials, as well as formulations, chemistry, and chemical characterization, under the same remuneration terms as previous agreements between the parties, with no cost duplication permitted.


Please enter your comment!
Please enter your name here